Analysts Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $122.70

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $124.20.

Several brokerages have commented on TMDX. Piper Sandler reaffirmed an “overweight” rating and issued a $105.00 price objective (up previously from $90.00) on shares of TransMedics Group in a research report on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $92.01 on Monday. The firm has a market cap of $3.11 billion, a price-to-earnings ratio of 97.88 and a beta of 2.14. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $177.37. The firm’s 50-day simple moving average is $75.41 and its two-hundred day simple moving average is $77.31.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of TransMedics Group by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company’s stock worth $226,700,000 after acquiring an additional 40,860 shares during the period. FIL Ltd boosted its stake in TransMedics Group by 28.0% during the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company’s stock valued at $62,372,000 after buying an additional 218,961 shares during the period. Braidwell LP bought a new stake in TransMedics Group during the fourth quarter valued at $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in TransMedics Group by 16.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company’s stock valued at $56,307,000 after buying an additional 128,474 shares during the period. Finally, Mackenzie Financial Corp boosted its stake in TransMedics Group by 73.0% during the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock valued at $51,635,000 after buying an additional 349,403 shares during the period. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.